“Repurposing Approved Drugs”

rmation that he's gotten from public sources and done data analysis on those sources to share with us today. But first let’s do a round of introductions to get a sense of the people that are drawn to Prostate Cancer Lab. Participant Introductions Mike Yancey: I'm here as a prostate cancer patient. I'm out of the Northeast Oklahoma area.

Brad Power: When you were diagnosed in Oklahoma, where did you get treatment? It's easy when we're on the coast or near an academic cancer research center, like Boston, or Houston, MD Anderson, San Diego, UCSF, or Seattle. Rick Davis: If he joins one of our groups, I'm sure we can help him solve that problem. I run AnCan.

We provide patient support to patients at all levels of prostate cancer from active surveillance, all the way up to advanced disease. And one of the things we do is navigate them if they are not getting the right sort of treatment. Karin Rodland: I'm a PhD cancer biologist. I've been interested in cancer for about 50 years.

My specialty is gynecological ovarian uterine, cervical cancer, but I've been involved at Pacific Northwest National Lab in a lot of tumor characterization studies organized by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) , which just covers a wide range of tumors. And we also have funding to do early detection and risk assessment in prostate cancer.

So basically I can help you navigate the literature. That's probably my most useful function. Brad Power: You're based in the Portland, Oregon, area? Karin Rodland: Yes. I'm an emeritus professor at Oregon Health Sciences University.

And to answer Mike's question, no matter where you are, if you don't have one of those named places nearby like MD Anderson or Mass General, find your state's academic medical center and get your care at your state's medical school academic center, because they will be the most cognizant of the research level of findings of anywhere in your state. And every state has one just about.

Sophia Cornew: Hi, I'm with the company Ciitizen that was acquired by Invitae last fall. We've supported a number of Brad's hackathons, mostly from a data infrastructure perspective. Our product allows patients to gather all of their medical records from all places of care, and consolidate it in one place that's easy to share. I like to call it a digital file cabinet.

“Repurposing Approved Drugs” (Saed Sayad) [#4] That sounds simple, but, when you've received tons of care and you're dispersed all over the place it can be quite helpful, especially for a hackathon like this, so that everyone can access it and work from the same clinical information. We are delighted to support these hackathons and would love the opportunity to support the patients participating.

I haven't been able to join because I have a conflicting meeting with the Leukemia and Lymphoma Society. We host their national registry.

nd work from the same clinical information. We are delighted to support these hackathons and would love the opportunity to support the patients participating. I haven't been able to join because I have a conflicting meeting with the Leukemia and Lymphoma Society. We host their national registry.

Now that we are part of Invitae, one of the things I'm excited to do is bring forth a lot of the research assays that may not necessarily be open to the general public yet. And there's definitely a lot of interest in the prostate cancer space from a hereditary and somatic perspective.

And so would love to bring in some of those kinds of scientific minds on our extended team and see if our lab can't also be of service to the hackathon. So wonderful to meet you all. And I'm so glad that I can be here in person versus watching the recordings and, and reading all the emails. It's so nice to meet everyone. Ken Anderson: I've known Brian for quite a while.

I'm a cancer patient who has been battling prostate cancer for almost six years now. I just got my first round of Lutetium. I have been pretty actively involved with AnCan. Chandra Cota: I'm a medical physicist working in radiation therapy. Brad always confuses me with a radiologist who reads images in radiology departments.

It just goes to show there are so many different subspecialties and niche fields within cancer care. It's just mind boggling for patients to keep track of who does what? In my day job I assist the doctors, as a radiation oncologist, delivering radiation treatments and think about better ways of radiation treatments, which are more effective for patients with fewer side effects.

I’m currently working at Yale in Connecticut, and I'm always looking to learn and help patients outside the traditional healthcare setting. I'm here to see how I can help patients and leverage technologies and advance the field so we can hope for better cures. Herb Geller: I am a prostate cancer patient.

I'm also a researcher and lab chief at the National Institutes of Health, where my specialty is neurobiology, but we use lots of different techniques, and I have published in the cancer field when I was part of the Rutgers Cancer Institute when I was a professor at Rutgers. I'm very interested in how we move ahead.

Laura Kleiman: I'm the founder and CEO of RebootRx, a nonprofit that is repurposing generic drugs for cancer, using AI technology that we're developing. Pradeep Mangalath: I'm the co-founder and CTO at RebootRx. We've worked with Brian in the past. I recognize most of you. It’s good to reconnect. Ally Perlina: I'm the chief science officer at CureMatch here in San Diego. I'm a San Diegan.

I've been attending quite a few of these hackathons and have been able to help in various ways and hoping to do more. I worked with Rick some time ago at Human Longevity.

“Repurposing Approved Drugs” (Saed Sayad) [#4]

e officer at CureMatch here in San Diego. I'm a San Diegan. I've been attending quite a few of these hackathons and have been able to help in various ways and hoping to do more. I worked with Rick some time ago at Human Longevity. I’m the kind of

“Repurposing Approved Drugs” (Saed Sayad) [#4] scientist who has very diverse, multifaceted expertise for about 20 years now, mostly with startups, specializing in systems biology approaches to impact clinical care. Usually when we hear systems biology, it's very much computationally focused, but I've been very close to the actual patient-physician interactions and decisions.

My mission has always been to take all of these expert interactions and then deliver them in ways that can be automated as much as possible to scale personalization with molecular level precision.

The way I always seek to help is to, first of all, provide input in any kind of analytics from bioinformatics to machine learning, to any sort of data science, even though I've never gotten very much technical and hands on, and I can't offer that right now, but I've done so much data analytics that I think I'll be able to at least chime in with input or questions because that goes for any type of data, from genomics to transcriptomics, of course, and metabolomics, even proteomics.

I also did a lot of work with the microbiome and actually invented some products that also do pathway and molecular profiling from different -omics, including microbiome and not only with pharmaceuticals, but nutraceutical agents. I was a primary inventor on a personalized supplements product, something I did before I came to CureMatch in 2020.

Happy to provide some insights there, but I just want to make sure that as, as a CureMatch representative, I seek to help get all of the markers that everybody deems as important, because I know this is a big part of these hackathons to figure out what is the list of markers that are important and then to take them into this many-to-many analysis, what are the drugs that best address most markers and what are the combinations that can be attempted and CureMatch will score that.

So I'm happy to run a report that will match basically any markers at any level. Rick Stanton: Thank you, Ally. You're terrific. I know from working together, when you grab onto a task, you're the kind of person we want in our corner. Brad Power: Ally will be doing an analysis of Rick and Brian's data and presenting that in the next week or two.

Rick Stanton: I wanted to give a quick shout out to Rick Davis. I got a communication from Dr. Tanya Dorff, saying that Pluvicto would be a great choice for me. Thank you so much, Rick, for bringing this to my attention.

This seems to make sense, and it wasn't brought up by my clinical oncologist team, and when you brought it up, I asked them about it, and they all said that it seems to make sense. It was just flabbergasting to me.